Related Experiment Video
Updated: Feb 25, 2026
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
24.1K
Allergen-specific intralymphatic immunotherapy in human and animal studies
Seon Tae Kim1, So Hyun Park2, Sang Min Lee3
1Department of Otolaryngology-Head and Neck Surgery, Gachon University Gil Medical Center, Incheon 21565, Korea.
Asia Pacific Allergy
|August 3, 2017
Summary
Intralymphatic immunotherapy (ILIT) shows promise in overcoming limitations of traditional allergy treatments. This review examines ILIT
Area of Science:
- Immunology
- Allergy Research
- Clinical Trials
Background:
- Conventional allergen-specific immunotherapy (SCIT/SLIT) faces challenges including long treatment durations and hypersensitivity reactions.
- Intralymphatic immunotherapy (ILIT) has emerged as a potential alternative to address these limitations.
- Translational and veterinary research has also explored ILIT in animal models.
Purpose of the Study:
- To conduct a comprehensive literature review on intralymphatic immunotherapy (ILIT).
- To evaluate the treatment efficacy of ILIT in clinical and preclinical settings.
- To assess the adverse effects associated with ILIT.
Main Methods:
- Systematic literature search for studies on intralymphatic immunotherapy.
- Inclusion of clinical trials and animal studies.
- Analysis of reported treatment outcomes and adverse events.
Main Results:
- ILIT demonstrates potential in overcoming limitations of conventional immunotherapy.
- Efficacy data from clinical trials and animal studies are being compiled.
- Adverse effect profiles are under examination to determine safety and tolerability.
Conclusions:
- Intralymphatic immunotherapy (ILIT) presents a promising approach for allergen-specific immunotherapy.
- Further research is warranted to fully establish the efficacy and safety of ILIT.
- ILIT may offer a more effective and tolerable alternative for managing allergic diseases.
